DP-b99 modulates matrix metalloproteinase activity and neuronal plasticity
- PLoS One. 2014 Jun 11;9(6):e99789. doi: 10.1371/journal.pone.0099789.
- 1. Department of Neurophysiology, The Nencki Institute of Experimental Biology, Warsaw, Poland.
- 2. Department of Molecular and Cellular Neurobiology, The Nencki Institute of Experimental Biology, Warsaw, Poland.
- 3. D-Pharm Ltd, Kiryat Weizmann Science Park, Rehovot, Israel.
- 4. Department of Neurobiology, Weizmann Institute, Rehovot, Israel.
DP-b99 is a membrane-activated chelator of zinc and calcium ions, recently proposed as a therapeutic agent. Matrix Metalloproteinases (MMPs) are zinc-dependent extracellularly operating proteases that might contribute to synaptic plasticity, learning and memory under physiological conditions. In excessive amounts these Enzymes contribute to a number of neuronal pathologies ranging from the stroke to neurodegeneration and epileptogenesis. In the present study, we report that DP-b99 delays onset and severity of PTZ-induced seizures in mice, as well as displays neuroprotective effect on kainate excitotoxicity in hippocampal organotypic slices and furthermore blocks morphological reorganization of the dendritic spines evoked by a major neuronal MMP, MMP-9. Taken together, our findings suggest that DP-b99 may inhibit neuronal plasticity driven by MMPs, in particular MMP-9, and thus may be considered as a therapeutic agent under conditions of aberrant plasticity, such as those subserving epileptogenesis.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
Research Areas: Neurological Disease